Match_Status;Product_ID;Product_Code;Product_Name;Modality;Classification;Product_Type;Therapeutic_Area;Current_Phase;Project_Status;Lead_Indication;Expected_Launch_Year;Timeline_Variance_Days;Launch_Geography;Commercial;Development_Approach;Development_Site;Launch_Site;Pharma_Form;Technology;Storage_Conditions;DS_Volume_Category;DP_Volume_Category;Route_Of_Administration;DS_Suppliers;DP_Suppliers;Device_Partners;Contact_Person;Strategic_Class;Strategic_Technology;Demand_Category;Peak_Demand_Range;Operational_Risks;Timeline_Risks;Supply_Chain_Risks;Mechanism_Of_Action;Short_Description;Patient_Population;Regulatory_Details;Submission_Status
NO_MATCH_export;Adalimumab;;;Monoclonal Antibody;Liquid;;;;;;;;;Make;INTERNAL;BI Biberach;BI Fremont;Sf_Injection;Sterile Filling;2 to 8°C;;;;;;;Vermani,Kavita (HP BioP NW) BIF-US-F;NBE;Device for s.c. injection;Very Low;<1 mio PCS;;;;;;;;
NO_MATCH_export;Adalimumab;;;Monoclonal Antibody;Liquid;;;;;;;;;Make;INTERNAL;BI Fremont;BI Fremont;Sf_Injection-HCLF;Sterile Filling;2 to 8°C;;;;;;;Vermani,Kavita (HP BioP NW) BIF-US-F;NBE;Device for s.c. injection;Low;1-10 mio PCS;;;;;;;;
MATCH;BI 1356225;BI 1356225;;Small Molecule;Solid;NME;Mental Health (Impulsivity in Substance Use Disorder);Phase I;On Track;Impulsivity/Substance Use Disorder (SuD) / Obesity;2034;0;;;tbd;(Blank);tbd;FC_Tablet;tbd;tbd;;;Oral;;;;May,Dr.,Sabine (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;(Blank);(Blank);;;;GOAT (Ghrelin O-acyltransferase) inhibitor.;"Oraler GOAT-Inhibitor zur Reduktion von Impulsivität bei Opioid-Use-Disorder; Präzisionspsychiatrie-Ansatz.";;;
MATCH;BI 1584862;BI 1584862;Not disclosed;Small Molecule;Solid;NME;Eye Health;Phase II;On Track;Geographic Atrophy (GA);2032;0;;Make (strat);EACD;BI Kobe, JP;tbd;FC_Tablet;Roller Compaction;tbd;;;Oral;EACD (ongoing);EACD (ongoing);;Lehnen,Dr.,Dominika (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;(Blank);(Blank);;;;PAFR (Platelet-Activating Factor Receptor) antagonist.;An oral PAFR antagonist for Geographic Atrophy (GA).;;;
MATCH;BI 1703880;BI 1703880;;Small Molecule;Liquid;NME;Oncology;Phase I;On Track;Non-Small Cell Lung Cancer (NSCLC);2032;0;;;CDMO;(Blank);tbd;Sf_Injection;Sterile Filling;(Blank);Low (10 - 1,000 kg);Very Low (< 1 million PCS);Injectable (SFInj);C(D)MO (ongoing);C(D)MO (ongoing);;Ruppert,Tanja (HP BioP L&I) BIP-DE-I;NCE_liquid;Vial (Standard);Very Low;<1 mio PCS;;;;Systemic 'Second-Generation' STING agonist.;Systemic STING agonist in Phase I combination trial for a broad range of solid tumors.;;;
MATCH;BI 1815368;BI 1815368;;Small Molecule;Solid;NME;Eye Health (DME-Fokus in laufender Entwicklung);Phase II;On Track;Wet AMD prevention (nAMDp);2032;0;;Make (strat);CDMO;Almac;BI Ingelheim;FC_Tablet;tbd;tbd;;;Oral;ING @Ingelheim (ongoing);;;Friccius,Klaus (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;(Blank);(Blank);;;;PKK (Plasma Kallikrein) inhibitor.;Oraler PKK-Inhibitor zur Behandlung des diabetischen Makulaödems (DME).;;;
MATCH_LE;BI 1815368;BI 1815368_NAMD;Not disclosed;Small Molecule;Solid;;Ophthalmology;;;nAMD Prevention;2035;;;Make (strat);CDMO;Almac;BI Ingelheim;FC_Tablet;tbd;tbd;;;Oral;;;;Friccius,Klaus (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;(Blank);(Blank);;;;Plasma Kallikrein (PKK) inhibitor - inhibits PKK to reduce vascular permeability and inflammation in retinal diseases.;Line extension of PKK inhibitor for prevention/adjunct treatment of neovascular age-related macular degeneration.;Patients at risk for or with early nAMD;;
MATCH;BI 1819479;BI 1819479;;Small Molecule;Solid;NME;"Respiratory; Immunology";Phase II;On Track;Idiopathic/Progressive Pulmonary Fibrosis (IPF/PPF);2031;0;;Buy;"INTERNAL;CDMO";Corden Pharma, Plankstadt;Corden Plankstadt;FC_Tablet;Fluid Bed Granulation;(Blank);Low (10 - 1,000 kg);Medium (10 - 100 million PCS);Oral;;Corden (ongoing);;Heblich,Dr.,Bettina (HP BioP L&I) BIP-DE-I;Solid;Solids non-standard;Medium;10-100 mio PCS;;;;Lysophospholipase inhibitor / Autotaxin (ATX) inhibitor.;An Autotaxin (ATX) inhibitor targeting the generation of lysophosphatidic acid (LPA) involved in fibrosis.;;;
MATCH;BI 1831169;BI 1831169;;Gene Therapy;Liquid;NBE;Oncology;Phase I;On Track;"Pancreatic Ductal Adenocarcinoma (PDAC); HNSCC; Melanoma";2034;0;;Buy;CDMO;Vibalogics;tbd;Sf_Injection;Sterile Filling;(Blank);High (> 30 12k runs);Very Low (< 1 million PCS);Intratumoral (i.t.) und Intravenös (i.v.);Lonza (ongoing);Lonza (ongoing);;Kuegler,Dr.,Markus (HP BioP L&I) BIP-DE-B;NBE_NTM;Vial (New Modalities);Very Low;(Blank);;;;VSV-GP OV (Vesicular Stomatitis Virus - Glycoprotein Oncolytic Virus).;An oncolytic virus gene therapy for solid tumors like PDAC, HNSCC, and Melanoma, administered intratumorally and intravenously.;;;
MATCH;BI 3000202;BI 3000202;;Small Molecule;Solid;NME;Immunology;Phase I;On Track;Systemic Sclerosis (SSc) / IFN (Interferonopathies);2032;0;;Make (strat);CDMO;Almac;BI Ingelheim;FC_Tablet;Fluid Bed Granulation;(Blank);;;Oral;C(D)MO (ongoing);C(D)MO (ongoing);;Friccius,Klaus (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;(Blank);(Blank);;;;cGAS inhibitor.;"Oraler cGAS-Inhibitor für SSc und monogene Interferonopathien; potenziell krankheitsmodifizierend.";;;
MATCH_LE;BI 3000202;BI 3000202_DF4;Not disclosed;Small Molecule;Solid;;Immunology / Autoinflammatory Diseases;;;Type I Interferonopathy dF4;2032;;;Make (strat);CDMO;Almac;BI Ingelheim;FC_Tablet;Fluid Bed Granulation;(Blank);;;Oral;;;;Friccius,Klaus (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;(Blank);(Blank);;;;cGAS inhibitor - inhibits cyclic GMP-AMP synthase, reducing type I interferon signaling.;Line extension of cGAS inhibitor for type I interferonopathy dF4 indication.;Patients with type I interferonopathy dF4;;
MATCH_LE;BI 3000202;BI 3000202_SSC;Not disclosed;Small Molecule;Solid;;Immunology;;;Systemic Sclerosis;2035;;;Make (strat);CDMO;Almac;BI Ingelheim;FC_Tablet;Fluid Bed Granulation;(Blank);;;Oral;;;;Friccius,Klaus (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;(Blank);(Blank);;;;cGAS inhibitor - inhibits cyclic GMP-AMP synthase, reducing type I interferon signaling and fibrosis.;Line extension of cGAS inhibitor for Systemic Sclerosis.;Patients with Systemic Sclerosis;;
MATCH;BI 3000202;BI 3000202;;Small Molecule;Solid;NME;Immunology;Phase I;On Track;Systemic Sclerosis (SSc) / IFN (Interferonopathies);2032;0;;Buy (strat);CDMO;Almac;Almac Charnwood;Oral Granules-PED;Fluid Bed Granulation;tbd;;;Oral;C(D)MO (ongoing);C(D)MO (ongoing);;Friccius,Klaus (HP BioP L&I) BIP-DE-I;Solid;Oral Granules;(Blank);(Blank);;;;cGAS inhibitor.;"Oraler cGAS-Inhibitor für SSc und monogene Interferonopathien; potenziell krankheitsmodifizierend.";;;
MATCH_LE;BI 3000202;BI 3000202_DF4;Not disclosed;Small Molecule;Solid;;Immunology / Autoinflammatory Diseases;;;Type I Interferonopathy dF4;2032;;;Buy (strat);CDMO;Almac;Almac Charnwood;Oral Granules-PED;Fluid Bed Granulation;tbd;;;Oral;;;;Friccius,Klaus (HP BioP L&I) BIP-DE-I;Solid;Oral Granules;(Blank);(Blank);;;;cGAS inhibitor - inhibits cyclic GMP-AMP synthase, reducing type I interferon signaling.;Line extension of cGAS inhibitor for type I interferonopathy dF4 indication.;Patients with type I interferonopathy dF4;;
MATCH_LE;BI 3000202;BI 3000202_SSC;Not disclosed;Small Molecule;Solid;;Immunology;;;Systemic Sclerosis;2035;;;Buy (strat);CDMO;Almac;Almac Charnwood;Oral Granules-PED;Fluid Bed Granulation;tbd;;;Oral;;;;Friccius,Klaus (HP BioP L&I) BIP-DE-I;Solid;Oral Granules;(Blank);(Blank);;;;cGAS inhibitor - inhibits cyclic GMP-AMP synthase, reducing type I interferon signaling and fibrosis.;Line extension of cGAS inhibitor for Systemic Sclerosis.;Patients with Systemic Sclerosis;;
MATCH;BI 3009947;BI 3009947;;Small Molecule;Solid;NME;Immunology;Pre-Clinical;Discontinued;"Systemic Sclerosis (SSc); IFN (Interferonopathies)";;0;;;tbd;(Blank);tbd;FC_Tablet;tbd;(Blank);;;Oral;;;;Schatter,Dr.,Beate (HP BioP L&I) BIP-DE-I;Solid;Technology unknown;(Blank);(Blank);;;;STING inhibitor.;STING inhibitor for systemic sclerosis and interferonopathies;;;
MATCH;BI 3009947;BI 3009947;;Small Molecule;Solid;NME;Immunology;Pre-Clinical;Discontinued;"Systemic Sclerosis (SSc); IFN (Interferonopathies)";;0;;;tbd;(Blank);tbd;Oral Granules-PED;tbd;(Blank);;;Oral;;;;Schatter,Dr.,Beate (HP BioP L&I) BIP-DE-I;Solid;Technology unknown;(Blank);(Blank);;;;STING inhibitor.;STING inhibitor for systemic sclerosis and interferonopathies;;;
MATCH;BI 3031185;BI 3031185;;Small Molecule;Solid;NME;Mental Health;Pre-Clinical;On Track;Impulsivity;2034;0;;tbd;;(Blank);tbd;FC_Tablet;tbd;tbd;;;Oral;;;;Lehnen,Dr.,Dominika (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;(Blank);(Blank);;;;mGluR4 NAM (Negative Allosteric Modulator).;An mGluR4 Negative Allosteric Modulator for Impulsivity.;;;
MATCH;BI 3032950;BI 3032950;;Monoclonal Antibody;Liquid;NBE;Immunology;Phase II;On Track;Crohn's Disease (CD);2034;0;;;CDMO;Lonza (Basel);tbd;Sf_Injection;Sterile Filling;2 to 8°C;;;IV (Induktion), SC (Erhaltung);;;;Goeggel,Dr.,Svenja (HP BioP L&I) BIP-DE-B;NBE;Device for s.c. injection;(Blank);(Blank);;;;TREM-1 antagonist.;"TREM-1 antibody for Ulcerative Colitis (induction i.v., maintenance s.c.); IBD program, CD in evaluation.";;;
MATCH;BI 3034701;BI 3034701;Not disclosed;Peptides;Liquid;NME;Cardiovascular-Renal-Metabolic (CRM);Phase I;On Track;Obesity (Overweight/Obesity BMI ≥27 kg/m²);2032;;;Make;INTERNAL;BI Biberach;tbd;Sf_Injection;Sterile Filling;2 to 8°C;;;Subcutaneous (presumed, typical for long-acting peptides);;;;Lindemann,Dr.,Eva (HP BioP L&I) BIP-DE-I;NCE_liquid;Device for s.c. injection;(Blank);(Blank);;;;Triple agonist targeting GLP-1R, GIPR, and NPY2R - simultaneous activation of three receptors involved in appetite regulation and energy homeostasis for weight management. Long-acting peptide therapeutic.;Long-acting triple agonist peptide (GLP-1R/GIPR/NPY2R) for obesity. Phase I study evaluating safety, tolerability, and pharmacokinetics in people with overweight/obesity.;Adults with overweight or obesity (BMI ≥27 kg/m²);Obesity: 1 designation;
MATCH;Bl 3720931;BI 3720931;;Gene Therapy;Liquid;NBE;Cystic Fibrosis (Respiratory);Phase I/II (Lenticlair-01 FIH started Nov 2024);Active;Cystic Fibrosis (CF);2032;0;;;CDMO;"Oxford Biomedica; Novalabs";tbd;Sf_Inhalation;Sterile Filling;-70°C;;;Inhalation (nebulized);;;;Goeggel,Dr.,Svenja (HP BioP L&I) BIP-DE-B;NBE_NTM;Inhaler;(Blank);(Blank);;;;Third-generation, self-inactivating lentiviral vector therapy for inhaled CFTR gene delivery.;Inhaled lentiviral gene therapy for cystic fibrosis.;;;
MATCH;BI 3776528;BI 3776528;;Small Molecule;Solid;NME;Mental Health – Cognitive impairment in PSD/Schizophrenia;Phase I (laufend);On Track;Cognitive Impairment Post-Stroke Depression (CI PSD);;0;;;tbd;(Blank);tbd;FC_Tablet;tbd;tbd;;;Oral;;;;Friccius,Klaus (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;(Blank);(Blank);;;;SSTR4 agonist.;Oraler SSTR4-Agonist zur Behandlung kognitiver Beeinträchtigung in PSD/SCZ-Spektrum.;;;
NO_MATCH_export;BI 3782253;;;UNKNOWN;Solid;;;;;;;;;tbd;tbd;(Blank);tbd;tbd;tbd;tbd;;;;;;;Barino,Frank (HP BioP L&I) BIP-DE-I;Solid;Technology unknown;(Blank);(Blank);;;;;;;;
MATCH;BI 3794407;BI 3794407;;Small Molecule;Solid;NME;Inflammation & Respiratory (I&R);Pre-Clinical;Discontinued;Systemic Sclerosis (SSc);;0;;;tbd;(Blank);tbd;FC_Tablet;tbd;tbd;;;oral;;;;Friccius,Klaus (HP BioP L&I) BIP-DE-I;Solid;Technology unknown;(Blank);(Blank);;;;cGAS inhibitor.;Oraler cGAS-Inhibitor für SSc und Typ-I-Interferonopathien (FU zum FR).;;;
NO_MATCH_export;BI 3797363;;;UNKNOWN;Solid;;;;;;;;;tbd;tbd;(Blank);tbd;tbd;tbd;tbd;;;;;;;Hartig-Heimel,Dr.,Mareke (HP BioP L&I) BIP-DE-I;Solid;Technology unknown;(Blank);(Blank);;;;;;;;
MATCH;BI 3798489;BI 3798489;BI 3798489;Peptides;Liquid;NME;Cardiovascular-Renal-Metabolic (CRM);Preclinical;;Obesity;2035;0;;;;(Blank);tbd;Sf_Injection;Sterile Filling;(Blank);;;SC injection;;;;;NCE_liquid;Technology unknown;(Blank);(Blank);HIGH: 1;;;NMUR2 agonist for obesity, targeting satiety circuits to reduce food intake and body weight.;NMUR2 agonist peptide for obesity.;"Patients with obesity; monthly dosing anticipated";;
MATCH;BI 3802876;BI 3802876;;Recombinant Proteins;Liquid;NBE;Cardiovascular-Renal-Metabolic (CRM);Phase I (laufend);On Track;MASH;;0;;;INTERNAL;BI Biberach;tbd;Sf_Injection;Sterile Filling;2 to 8°C;;;IV;;;;Luenser-Diez,Dr.,Katja (HP BioP L&I) BIP-DE-B;NBE;Technology unknown;(Blank);(Blank);;;;FAP-verankerter TRAILR2-Agonist (HSC-Ziel).;A FAP-TRAILR2 agonist for MASH.;;;
MATCH;BI 3804379;BI 3804379;;Recombinant Proteins;Liquid;NBE;Cardiovascular-Renal-Metabolic (CRM);Phase I (laufend);On Track;MASH;;0;;;INTERNAL;Biberach;tbd;Sf_Injection;Sterile Filling;2 to 8°C;;;SC und IV;;;;Goeggel,Dr.,Svenja (HP BioP L&I) BIP-DE-B;NBE;Technology unknown;(Blank);(Blank);;;;Anti-IL11;An injectable recombinant protein for MASH.;;;
MATCH;BI 3810477;BI 3810477;;Monoclonal Antibody;Liquid;NBE;Inflammation & Respiratory;Phase I;Active;IPF/PPF;2034;0;;;tbd;(Blank);tbd;Sf_Injection;tbd;2 to 8°C;;;i.v. und s.c.;;;;Becker,Dr.,Eric (HP BioP L&I) BIP-DE-B;NBE;Vial (Standard);(Blank);(Blank);;;;Binds a unique CTGF epitope, preventing cell surface binding and MMP7-mediated CTGF cleavage.;Humanized IgG1 mAb against CTGF for IPF/PPF.;;;
MATCH;BI 3810944;BI 3810944;;Recombinant Proteins;Liquid;NBE;Oncology;Phase I;On Track;Melanoma;2032;0;;;;(Blank);tbd;Sf_Injection;Sterile Filling;(Blank);;;;;;;Luenser-Diez,Dr.,Katja (HP BioP L&I) BIP-DE-B;NBE;Vial (Standard);(Blank);(Blank);;;;Kollagenbindende, MMP9-aktivierte IL-12-Prodrug (ODC).;"Systemische ODC-IL12-Prodrug; sentinel indication Melanoma.";;;
MATCH;BI 3812465;BI 3812465;;Recombinant Proteins;Liquid;NBE;Ophthalmology (CI-DME);Phase I;;CI-DME;2032;0;;tbd;;(Blank);tbd;Sf_Injection;Sterile Filling;tbd;;;Intravitreal;;;;Trischler,Dr.,Martin (HP BioP L&I) BIP-DE-B;NBE;IVT;(Blank);(Blank);HIGH: 1;;;Bispecific FZD4/LRP5-Modulator (Wnt-/Norrin-Mimetikum) to mimic Norrin and activate Wnt/β-catenin signaling, restoring BRB integrity.;Bispecific Wnt-pathway FZD4/LRP5-Modulator for CI-DME to restore BRB integrity.;Patients with chronic diabetic macular edema (CI-DME);;
MATCH;BI 3814916;BI 3814916;Not yet assigned;Monoclonal Antibody;Liquid;NBE;Hepatologie (ACLF);Phase I;;MASH;2034;0;;Make;INTERNAL;BI Biberach;tbd;Sf_Injection;Sterile Filling;tbd;;;parenteral (i.v. oder s.c.);;;;Malcher,Desiree (HP BioP L&I) BIP-DE-B;NBE;Device for s.c. injection;(Blank);(Blank);HIGH: 3;;;Anti-TLR4 monoclonal antibody.;Anti-TLR4 monoclonal antibody for Acute-on-Chronic Liver Failure (ACLF).;;;
MATCH;BI 3819026;BI 3819026;Anti-LAYN antibody;Monoclonal Antibody;Liquid;NBE;Oncology;Phase I (FIH);;Solid Tumors;2035;0;;tbd;tbd;(Blank);tbd;Sf_Infusion;tbd;tbd;;;intravenöse Infusion;;;;Trischler,Dr.,Martin (HP BioP L&I) BIP-DE-B;NBE;Technology unknown;(Blank);(Blank);MED: 1;;;Humanized IgG1 anti-LAYN antibody targeting LAYN isoforms 1 and 2 to deplete tumor-resident Tregs and enhance anti-tumor immunity, with demonstrated CD16a binding. Afucosylation is not definitively documented.;IgG1 antibody targeting LAYN to deplete tumor Tregs in solid tumors, with demonstrated CD16a binding for enhanced ADCC.;Solid tumors with high Treg infiltration.;;
MATCH;BI 3820768;BI 3820768;;T-cell Engager;Liquid;NBE;Oncology (Solid Tumors);Preclinical;;3L Endometrial Cancer (ALPG+);2031;0;US;tbd;tbd;(Blank);tbd;Sf_Injection;tbd;tbd;Low volume;Low volume;Intravenous (to be confirmed);;;;Kuegler,Dr.,Markus (HP BioP L&I) BIP-DE-B;NBE;Technology unknown;(Blank);(Blank);HIGH: 1;;;Bispecific antibody in 2+1 format engaging ALPG on tumor cells and CD3 on T‑cells to induce targeted cytotoxicity and immune activation.;Bispecific TcE targeting ALPG and CD3 for solid tumors;Adults with ALPG+ tumors (initial focus on endometrial cancer);;"No active submissions; FiH preparation ongoing"
NO_MATCH_export;BI 3828540;;;UNKNOWN;Liquid;;;;;;;;;tbd;;(Blank);tbd;Sf_Injection;Sterile Filling;(Blank);;;;;;;Lindemann,Dr.,Eva (HP BioP L&I) BIP-DE-I;NBE;Technology unknown;(Blank);(Blank);;;;;;;;
MATCH;"BI 3907074; BI 3907075; BI 3720590";BI 3907074 / BI 3907075 / BI 3720590;;Gene Therapy;Liquid;NBE;Oncology;Pre-Clinical;On Track;Pancreatic Ductal Adenocarcinoma (PDAC);2034;0;;;;(Blank);tbd;Sf_Injection;Sterile Filling;;;;;;;;Kuegler,Dr.,Markus (HP BioP L&I) BIP-DE-B;NBE_NTM;Vial (New Modalities);(Blank);(Blank);;;;Kombination aus KISIMA-Impfkonstrukten (ATP150/152) und VSV-GP onkolytischem Vektor (154).;A complex gene therapy combining multiple proteins (KISIMA) and an oncolytic virus for Pancreatic Ductal Adenocarcinoma (PDAC).;;;
NO_MATCH_export;"BI 3907074; BI 3907075; BI 3720590";;;UNKNOWN;Liquid;;;;;;;;;;;(Blank);tbd;Sf_Injection;Sterile Filling;;;;;;;;Kuegler,Dr.,Markus (HP BioP L&I) BIP-DE-B;NBE_NTM;Vial (New Modalities);(Blank);(Blank);;;;;;;;
NO_MATCH_export;"BI 3907074; BI 3907075; BI 3720590";;;UNKNOWN;Liquid;;;;;;;;;;;(Blank);tbd;Sf_Injection;Sterile Filling;;;;;;;;Kuegler,Dr.,Markus (HP BioP L&I) BIP-DE-B;NBE_NTM;Vial (New Modalities);(Blank);(Blank);;;;;;;;
MATCH;BI 3923948;BI 3923948;Not disclosed;Gene Therapy;Liquid;NME;Oncology;Pre-Clinical (IMPD submitted September 2025);On Track;Triple-Negative Breast Cancer (TNBC);2034;;;Buy;CDMO;(Blank);tbd;Sf_Injection;Sterile Filling;(Blank);;;To be determined (likely intratumoral or intravenous);;;;Kuegler,Dr.,Markus (HP BioP L&I) BIP-DE-B;NBE_NTM;Vial (New Modalities);(Blank);(Blank);MED: 2;;;VSV-GP oncolytic virus with GSDME-IL12 payload - combines productive tumor cell infection and oncolysis (VSV-GP platform) with GSDME-mediated immunogenic cell death and IL-12-driven CD8+ T-cell activation to 'heat up' the tumor microenvironment.;Oncolytic virus platform for triple-negative breast cancer. VSV-GP vector carrying GSDME and IL-12 transgenes for combined oncolysis and immune activation.;Patients with triple-negative breast cancer;;
NO_MATCH_export;BI 3935509;;;Peptides;Liquid;;;;;;;;;tbd;tbd;(Blank);tbd;Sf_Injection;tbd;tbd;;;;;;;Lindemann,Dr.,Eva (HP BioP L&I) BIP-DE-I;NCE_liquid;tbd;(Blank);(Blank);;;;;;;;
MATCH;BI 3940749;BI 3940749;Not disclosed;Small Molecule;Solid;NME;Oncology;Pre-Clinical (FIH Q2/2026);On Track;Solid tumors with KRAS drivers (CRC, NSCLC, PDAC);2031;;;tbd;INTERNAL;EACD;tbd;tbd;tbd;tbd;;;Oral;ING (development);;;Thomas,Dr.,Johannes (HP BioP L&I) BIP-DE-I;Solid;Technology unknown;(Blank);(Blank);HIGH: 1;;;KRAS multi-degrader (PROTAC) - uses CRBN-mediated ubiquitination to induce proteasomal degradation of KRAS proteins. Pan-KRAS approach targeting multiple KRAS mutations through targeted protein degradation via E3 ligase CRBN.;Pan-KRAS PROTAC degrader for solid tumors with KRAS drivers (PDAC, NSCLC, CRC). Oral small molecule using CRBN E3 ligase for protein degradation.;Patients with KRAS-driven solid tumors including pancreatic cancer, non-small cell lung cancer, and colorectal cancer;;
NO_MATCH_export;BI 3955569;;;Small Molecule;Solid;;;;;;;;;tbd;tbd;(Blank);tbd;FC_Tablet;tbd;(Blank);;;;;;;Raabe,Dr.,Angela (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;(Blank);(Blank);;;;;;;;
MATCH;BI 3968621;BI 3968621;Not disclosed;Small Molecule;Solid;NME;Oncology;Preclinical;;RCC;2035;0;;tbd;tbd;(Blank);tbd;FC_Tablet;tbd;tbd;;;Oral;;;;Thomas,Steffi (HP BioP L&I) BIP-DE-I;Solid;Technology unknown;(Blank);(Blank);HIGH: 2;;;"PROTAC targeting HPK1 for proteasomal degradation via CRBN E3 ligase recruitment; enhances T/B/DC activation to boost anti-tumor immunity.";"Oral PROTAC degrading HPK1 to boost immune activation for RCC; preclinical development.";;;
NO_MATCH_export;BI 39720080 (CT-155);;;Prescription Digital Therapeutic (SaMD/PDT);Digital;;;;;;;;;;;(Blank);;;;(Blank);;;;;;;;Digital;Digital;;;;;;;;;;
NO_MATCH_export;BI 3986283;;;Peptides;Liquid;;;;;;;;;tbd;tbd;(Blank);tbd;Sf_IVT_Injection;Sterile Filling;tbd;;;;;;;;NCE_liquid;IVT;(Blank);(Blank);;;;;;;;
NO_MATCH_export;BI 4009032;;;ADC;Liquid;;;;;;;;;tbd;tbd;(Blank);tbd;Sf_IVT_Injection;Sterile Filling;tbd;;;;;;;;NBE_NTM;ADC;(Blank);(Blank);;;;;;;;
NO_MATCH_export;BI 4015092;;;Small Molecule;Solid;;;;;;;;;tbd;tbd;(Blank);tbd;FC_Tablet;tbd;(Blank);;;;;;;;Solid;Film-coated tablet;(Blank);(Blank);;;;;;;;
MATCH;BI 764198;BI 764198;Not disclosed;Small Molecule;Solid;NME;Nephrology / Renal;Phase II;On Track;Focal Segmental Glomerulosclerosis (FSGS);2031;;;Make;CDMO;Almac;BI Ingelheim;FC_Tablet;Roller Compaction;Room Temp.;;;Oral;;;;Ruppert,Tanja (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;Medium;10-100 mio PCS;;;;TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6.;TRPC6 inhibitor for renal diseases, primarily targeting FSGS (Focal Segmental Glomerulosclerosis).;Patients with FSGS and other proteinuric kidney diseases;;
MATCH_LE;BI 764198;BI 764198_DMD;Not disclosed;Small Molecule;Solid;;Neuromuscular Disorders;;;Duchenne Muscular Dystrophy;2032;;;Make;CDMO;Almac;BI Ingelheim;FC_Tablet;Roller Compaction;Room Temp.;;;Oral;;;;Ruppert,Tanja (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;Medium;10-100 mio PCS;;;;TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6.;Line extension of TRPC6 inhibitor for Duchenne Muscular Dystrophy.;Patients with Duchenne Muscular Dystrophy;;
MATCH_LE;BI 764198;BI 764198_PODO;Not disclosed;Small Molecule;Solid;;Nephrology / Renal;;;Podocytopathies;2034;;;Make;CDMO;Almac;BI Ingelheim;FC_Tablet;Roller Compaction;Room Temp.;;;Oral;;;;Ruppert,Tanja (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;Medium;10-100 mio PCS;;;;TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6.;Line extension of TRPC6 inhibitor for podocyte-related kidney diseases.;Patients with podocytopathies;;
MATCH_LE;BI 764198;BI 764198_PED;Not disclosed;Small Molecule;Solid;;Nephrology / Renal;Pre-Clinical;;FSGS Pediatric;2035;;;Make;CDMO;Almac;BI Ingelheim;FC_Tablet;Roller Compaction;Room Temp.;;;Oral;;;;Ruppert,Tanja (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;Medium;10-100 mio PCS;;;;TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6.;Pediatric line extension of TRPC6 inhibitor for FSGS in pediatric populations.;Pediatric patients with FSGS;;
MATCH;BI 764198;BI 764198;Not disclosed;Small Molecule;Solid;NME;Nephrology / Renal;Phase II;On Track;Focal Segmental Glomerulosclerosis (FSGS);2031;;;Buy;CDMO;Almac;tbd;Oral Granules-PED;tbd;Room Temp.;;;Oral;;;;Ruppert,Tanja (HP BioP L&I) BIP-DE-I;Solid;Oral Granules;(Blank);(Blank);;;;TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6.;TRPC6 inhibitor for renal diseases, primarily targeting FSGS (Focal Segmental Glomerulosclerosis).;Patients with FSGS and other proteinuric kidney diseases;;
MATCH_LE;BI 764198;BI 764198_DMD;Not disclosed;Small Molecule;Solid;;Neuromuscular Disorders;;;Duchenne Muscular Dystrophy;2032;;;Buy;CDMO;Almac;tbd;Oral Granules-PED;tbd;Room Temp.;;;Oral;;;;Ruppert,Tanja (HP BioP L&I) BIP-DE-I;Solid;Oral Granules;(Blank);(Blank);;;;TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6.;Line extension of TRPC6 inhibitor for Duchenne Muscular Dystrophy.;Patients with Duchenne Muscular Dystrophy;;
MATCH_LE;BI 764198;BI 764198_PODO;Not disclosed;Small Molecule;Solid;;Nephrology / Renal;;;Podocytopathies;2034;;;Buy;CDMO;Almac;tbd;Oral Granules-PED;tbd;Room Temp.;;;Oral;;;;Ruppert,Tanja (HP BioP L&I) BIP-DE-I;Solid;Oral Granules;(Blank);(Blank);;;;TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6.;Line extension of TRPC6 inhibitor for podocyte-related kidney diseases.;Patients with podocytopathies;;
MATCH_LE;BI 764198;BI 764198_PED;Not disclosed;Small Molecule;Solid;;Nephrology / Renal;Pre-Clinical;;FSGS Pediatric;2035;;;Buy;CDMO;Almac;tbd;Oral Granules-PED;tbd;Room Temp.;;;Oral;;;;Ruppert,Tanja (HP BioP L&I) BIP-DE-I;Solid;Oral Granules;(Blank);(Blank);;;;TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6.;Pediatric line extension of TRPC6 inhibitor for FSGS in pediatric populations.;Pediatric patients with FSGS;;
MATCH;BI 764198;BI 764198;Not disclosed;Small Molecule;Liquid;NME;Nephrology / Renal;Phase II;On Track;Focal Segmental Glomerulosclerosis (FSGS);2031;;;tbd;CDMO;CDMO;tbd;Sf_Injection;tbd;(Blank);;;Oral;;;;Ruppert,Tanja (HP BioP L&I) BIP-DE-I;NCE_liquid;Vial (Standard);(Blank);(Blank);;;;TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6.;TRPC6 inhibitor for renal diseases, primarily targeting FSGS (Focal Segmental Glomerulosclerosis).;Patients with FSGS and other proteinuric kidney diseases;;
MATCH_LE;BI 764198;BI 764198_DMD;Not disclosed;Small Molecule;Liquid;;Neuromuscular Disorders;;;Duchenne Muscular Dystrophy;2032;;;tbd;CDMO;CDMO;tbd;Sf_Injection;tbd;(Blank);;;Oral;;;;Ruppert,Tanja (HP BioP L&I) BIP-DE-I;NCE_liquid;Vial (Standard);(Blank);(Blank);;;;TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6.;Line extension of TRPC6 inhibitor for Duchenne Muscular Dystrophy.;Patients with Duchenne Muscular Dystrophy;;
MATCH_LE;BI 764198;BI 764198_PODO;Not disclosed;Small Molecule;Liquid;;Nephrology / Renal;;;Podocytopathies;2034;;;tbd;CDMO;CDMO;tbd;Sf_Injection;tbd;(Blank);;;Oral;;;;Ruppert,Tanja (HP BioP L&I) BIP-DE-I;NCE_liquid;Vial (Standard);(Blank);(Blank);;;;TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6.;Line extension of TRPC6 inhibitor for podocyte-related kidney diseases.;Patients with podocytopathies;;
MATCH_LE;BI 764198;BI 764198_PED;Not disclosed;Small Molecule;Liquid;;Nephrology / Renal;Pre-Clinical;;FSGS Pediatric;2035;;;tbd;CDMO;CDMO;tbd;Sf_Injection;tbd;(Blank);;;Oral;;;;Ruppert,Tanja (HP BioP L&I) BIP-DE-I;NCE_liquid;Vial (Standard);(Blank);(Blank);;;;TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6.;Pediatric line extension of TRPC6 inhibitor for FSGS in pediatric populations.;Pediatric patients with FSGS;;
MATCH;BI 764524;BI 764524;Not disclosed;Monoclonal Antibody;Liquid;NME;Ophthalmology;Phase II;On Track;Diabetic Retinopathy (DR);2031;;;Buy;INTERNAL;BI Biberach;Vetter Ravensburg;Sf_Injection;Sterile Filling;2 to 8°C;;;Intravitreal;;;;Trischler,Dr.,Martin (HP BioP L&I) BIP-DE-B;NBE;IVT;Low;1-10 mio PCS;;;;Anti-Semaphorin 3A (anti-Sema3A) antibody - targets SEMA3A, a protein implicated in retinal vascular and neuronal pathology.;Anti-Sema3A antibody for retinal diseases, primarily targeting Diabetic Retinopathy.;Patients with Diabetic Retinopathy;;
MATCH_LE;BI 764524;BI 764524_DME;Not disclosed;Monoclonal Antibody;Liquid;;Ophthalmology;;;CI-DME;2032;;;Buy;INTERNAL;BI Biberach;Vetter Ravensburg;Sf_Injection;Sterile Filling;2 to 8°C;;;Intravitreal;;;;Trischler,Dr.,Martin (HP BioP L&I) BIP-DE-B;NBE;IVT;Low;1-10 mio PCS;;;;Anti-Semaphorin 3A (anti-Sema3A) antibody - targets SEMA3A, a protein implicated in retinal vascular and neuronal pathology.;Line extension of anti-Sema3A antibody for center-involved diabetic macular edema.;Patients with CI-DME;;
MATCH_LE;BI 764524;BI 764524_IRVO;Not disclosed;Monoclonal Antibody;Liquid;;Ophthalmology;;;iRVO;2032;;;Buy;INTERNAL;BI Biberach;Vetter Ravensburg;Sf_Injection;Sterile Filling;2 to 8°C;;;Intravitreal;;;;Trischler,Dr.,Martin (HP BioP L&I) BIP-DE-B;NBE;IVT;Low;1-10 mio PCS;;;;Anti-Semaphorin 3A (anti-Sema3A) antibody - targets SEMA3A, a protein implicated in retinal vascular and neuronal pathology.;Line extension of anti-Sema3A antibody for macular edema following retinal vein occlusion.;Patients with iRVO;;
MATCH;BI 765049;BI 765049;Not disclosed;T-cell Engager;Liquid;NME;Oncology;Phase I;On Track;Colorectal Cancer (CRC);2030;;;Make;INTERNAL;BI Biberach;BI Biberach;Sf_Injection;"Sterile Filling; Lyophilization";2 to 8°C;;;Intravenous;;;;Lindemann,Dr.,Eva (HP BioP L&I) BIP-DE-I;NBE;Vial (Standard);Very Low;<1 mio PCS;;;;B7-H6/CD3 bispecific T-cell engager - binds B7-H6 on tumor cells and CD3 on T-cells to activate immune response against cancer cells.;B7-H6/CD3 bispecific T-cell engager for colorectal cancer. First-in-human Phase I as monotherapy and in combination with PD-1 inhibitor ezabenlimab.;Patients with advanced colorectal cancer and other gastrointestinal malignancies;;
MATCH;BI 765179;BI 765179;Not disclosed;Monoclonal Antibody;Liquid;NME;Oncology;Phase Ib;On Track;Head and Neck Squamous Cell Carcinoma (HNSCC), First-Line PD-L1+;2031;;;Make;;(Blank);BI Biberach;Sf_Injection;Sterile Filling;tbd;;;Intravenous;;;;Lindemann,Dr.,Eva (HP BioP L&I) BIP-DE-I;NBE;Vial (Standard);Very Low;<1 mio PCS;;;;CD137-FAP bispecific agonist antibody - provides tumor-restricted CD137 activation through cancer-associated fibroblast (CAF) targeting via FAP.;CD137-FAP bispecific agonist antibody for head and neck squamous cell carcinoma. Phase Ib in combination with pembrolizumab for first-line PD-L1+ HNSCC.;Patients with PD-L1+ head and neck squamous cell carcinoma, first-line treatment;;
MATCH;BI 765423;BI 765423;;Monoclonal Antibody;Liquid;NBE;Respiratory;Phase I;On Track;Idiopathic/Progressive Pulmonary Fibrosis (IPF/PPFr);2034;0;;;CDMO;Lonza (Basel);tbd;Sf_Injection;Sterile Filling;2 to 8°C;;;Injectable (SFInj);;;;Goeggel,Dr.,Svenja (HP BioP L&I) BIP-DE-B;NBE;Vial (Standard);(Blank);(Blank);;;;IL-11 blockade by binding to soluble IL-11 and preventing the IL-11/IL-11R interaction.;An anti-IL11 antibody designed to block the IL-11 cytokine implicated in fibrotic lung diseases.;;;
MATCH;BI 770371;BI 770371;Not disclosed;Recombinant Proteins;Liquid;NME;Oncology;Phase I/II;On Track;Head and Neck Squamous Cell Carcinoma (HNSCC);2032;;;Make;INTERNAL;BI Biberach;BI Biberach;Sf_Injection;Sterile Filling;2 to 8°C;;;Intravenous;;;;Trischler,Dr.,Martin (HP BioP L&I) BIP-DE-B;NBE;Vial (Standard);(Blank);(Blank);;;;SIRPα antagonist - blocks the Signal Regulatory Protein alpha (SIRPα) to enhance macrophage-mediated tumor cell phagocytosis.;SIRPα antagonist for oncology, primarily targeting Head and Neck Squamous Cell Carcinoma.;Patients with HNSCC;;
MATCH_LE;BI 770371;BI 770371_MASH;Not disclosed;Recombinant Proteins;Liquid;;Hepatology / CRM;;;MASH;2034;;;Make;INTERNAL;BI Biberach;BI Biberach;Sf_Injection;Sterile Filling;2 to 8°C;;;Intravenous;;;;Trischler,Dr.,Martin (HP BioP L&I) BIP-DE-B;NBE;Vial (Standard);(Blank);(Blank);;;;SIRPα antagonist - blocks the Signal Regulatory Protein alpha (SIRPα) to enhance macrophage-mediated phagocytosis and reduce inflammation.;Line extension of SIRPα antagonist for MASH, targeting inflammatory pathways in metabolic liver disease.;Patients with MASH;;
MATCH;BI771716;BI 771716;Not disclosed;Monoclonal Antibody;Liquid;NME;Ophthalmology / Retinal Health;Phase II;On Track;Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD);2030;;;Buy;"INTERNAL;CDMO";"BI Biberach; Vetter Ravensburg";"Vetter Ravensburg; BI Biberach";Sf_Injection;Sterile Filling;2 to 8°C;;;Intravitreal injection (IVT);RCV @Biberach/Vienna network (active);;;Malcher,Desiree (HP BioP L&I) BIP-DE-B;NBE;IVT;Low;1-10 mio PCS;MED: 2;;;Anti-C3/C3b antibody fragment (scFv) - highly specific single-chain variable fragment targeting C3 and C3b, inhibiting complement activation via all three pathways (classical, lectin, and alternative).;Anti-C3 antibody fragment (scFv) for Geographic Atrophy secondary to AMD. Intravitreal injection showing >90% reduction of free C3 in aqueous humor. Phase II VERDANT study active comparing q4w and q8w regimens vs pegcetacoplan.;Patients with Geographic Atrophy secondary to AMD;;
NO_MATCH_export;CT-156-N/A;;;Prescription Digital Therapeutic (SaMD/PDT);Digital;;;;;;;;;;;(Blank);;;;(Blank);;;;;;;D&DL-OPS:;Digital;Digital;;;;;;;;;;
NO_MATCH_export;Empagliflozin;;;Small Molecule;Solid;;;;;;;;;Make;;(Blank);BI Ingelheim;FC_Tablet;High Shear Granulation;Room Temp.;;;;;;;Thomas,Dr.,Johannes (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;High;>100 mio PCS;;;;;;;;
NO_MATCH_export;Empagliflozin;;;Small Molecule;Solid;;;;;;;;;Buy;;(Blank);Rottendorf Pharma GmbH;FC_Tablet-PED;High Shear Granulation;(Blank);;;;;;;Thomas,Dr.,Johannes (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;(Blank);(Blank);;;;;;;;
MATCH;Ezabenlimab;BI 754091;Ezabenlimab;Monoclonal Antibody;Liquid;NBE;Oncology;Phase I/II (laufende Kombinationsprogramme);On Track;IV formulation for use in Oncology combinations.;;0;;Make;INTERNAL;BI Biberach;BI Biberach;Sf_Injection;Sterile Filling;(Blank);Low (6 - 15 12k runs);Low (1 - 10 million PCS);Intravenous (IV);Fremont @Fremont (ongoing);BC_F113 @Biberach (ongoing);;Lischewski,Dr.,Axel (HP BioP L&I) BIP-DE-I;NBE;Vial (Standard);Very Low;<1 mio PCS;;;;A humanized programmed cell death 1 (PD-1)-targeting monoclonal antibody.;PD-1 antibody as a combination backbone (e.g., with TcEs, STING-Ago., SIRPα-Antag., MDM2-Inhib.).;;;
NO_MATCH_export;Linagliptin;;;Small Molecule;Solid;;;;;;;;;Make;tbd;(Blank);tbd;FC_Tablet;tbd;(Blank);;;;;;;;Solid;Film-coated tablet;(Blank);(Blank);;;;;;;;
MATCH;Nerandomilast;BI 1015550;Nerandomilast;Small Molecule;Solid;NME;"Respiratory (IPF; PPF in Zulassung)";Approved/Launched (US, 09-Oct-2025, IPF);On Track;Idiopathic Pulmonary Fibrosis (IPF);2025;-10;"US; China";Make;INTERNAL;BI Biberach;BI Ingelheim;FC_Tablet;Twin Screw Granulation;Room Temp.;Low (10 - 1,000 kg);Medium (10 - 100 million PCS);Oral;ING @Ingelheim (qualified);"ING_SoL @Ingelheim (launch_ready); Koropi (transfer_ongoing)";;Meusel,Dr.,Manuela (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;High;>100 mio PCS;HIGH: 1;MED: 1;;An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B).;Oraler PDE4B-Inhibitor, der den FVC-Rückgang bei IPF signifikant verlangsamt (Phase-3).;;IPF: 2 designations;Submitted
MATCH_LE;Nerandomilast;BI 1015550_PPF;Nerandomilast;Small Molecule;Solid;;Respiratory;Phase III;On Track;Progressive Pulmonary Fibrosis;2026;;;Make;INTERNAL;BI Biberach;BI Ingelheim;FC_Tablet;Twin Screw Granulation;Room Temp.;;;Oral;;;;Meusel,Dr.,Manuela (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;High;>100 mio PCS;;;;An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B).;Line extension of Nerandomilast for Progressive Pulmonary Fibrosis. Phase III development.;;;
MATCH_LE;Nerandomilast;BI 1015550_MYO;Nerandomilast;Small Molecule;Solid;;Immunology;;;Myositis;2030;;;Make;INTERNAL;BI Biberach;BI Ingelheim;FC_Tablet;Twin Screw Granulation;Room Temp.;;;Oral;;;;Meusel,Dr.,Manuela (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;High;>100 mio PCS;;;;An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B).;Line extension of Nerandomilast for Myositis indication.;;;
MATCH_LE;Nerandomilast;BI 1015550_PED;Nerandomilast;Small Molecule;Solid;;Respiratory;Pre-Clinical;On Track;Pediatric Pulmonary Fibrosis;2030;;;Make;INTERNAL;BI Biberach;BI Ingelheim;FC_Tablet;Twin Screw Granulation;Room Temp.;;;Oral;;;;Meusel,Dr.,Manuela (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;High;>100 mio PCS;;;;An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B).;Pediatric line extension of Nerandomilast for pulmonary fibrosis. Uses different manufacturing process (Fluid Bed, outsourced to Almac).;;;
MATCH_LE;Nerandomilast;BI 1015550_SSC;Nerandomilast;Small Molecule;Solid;;Immunology;Phase II;On Track;Systemic Sclerosis;2030;;;Make;INTERNAL;BI Biberach;BI Ingelheim;FC_Tablet;Twin Screw Granulation;Room Temp.;;;Oral;;;;Meusel,Dr.,Manuela (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;High;>100 mio PCS;;;;An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B).;Line extension of Nerandomilast for Systemic Sclerosis. Phase II development.;;;
MATCH;Nerandomilast;BI 1015550;Nerandomilast;Small Molecule;Solid;NME;"Respiratory (IPF; PPF in Zulassung)";Approved/Launched (US, 09-Oct-2025, IPF);On Track;Idiopathic Pulmonary Fibrosis (IPF);2025;-10;"US; China";Buy;CDMO;Almac, UK;Almac Charnwood;Oral Granules-PED;tbd;Room Temp.;Low (10 - 1,000 kg);Medium (10 - 100 million PCS);Oral;ING @Ingelheim (qualified);"ING_SoL @Ingelheim (launch_ready); Koropi (transfer_ongoing)";;Meusel,Dr.,Manuela (HP BioP L&I) BIP-DE-I;Solid;Oral Granules;(Blank);(Blank);HIGH: 1;MED: 1;;An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B).;Oraler PDE4B-Inhibitor, der den FVC-Rückgang bei IPF signifikant verlangsamt (Phase-3).;;IPF: 2 designations;Submitted
MATCH_LE;Nerandomilast;BI 1015550_PPF;Nerandomilast;Small Molecule;Solid;;Respiratory;Phase III;On Track;Progressive Pulmonary Fibrosis;2026;;;Buy;CDMO;Almac, UK;Almac Charnwood;Oral Granules-PED;tbd;Room Temp.;;;Oral;;;;Meusel,Dr.,Manuela (HP BioP L&I) BIP-DE-I;Solid;Oral Granules;(Blank);(Blank);;;;An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B).;Line extension of Nerandomilast for Progressive Pulmonary Fibrosis. Phase III development.;;;
MATCH_LE;Nerandomilast;BI 1015550_MYO;Nerandomilast;Small Molecule;Solid;;Immunology;;;Myositis;2030;;;Buy;CDMO;Almac, UK;Almac Charnwood;Oral Granules-PED;tbd;Room Temp.;;;Oral;;;;Meusel,Dr.,Manuela (HP BioP L&I) BIP-DE-I;Solid;Oral Granules;(Blank);(Blank);;;;An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B).;Line extension of Nerandomilast for Myositis indication.;;;
MATCH_LE;Nerandomilast;BI 1015550_PED;Nerandomilast;Small Molecule;Solid;;Respiratory;Pre-Clinical;On Track;Pediatric Pulmonary Fibrosis;2030;;;Buy;CDMO;Almac, UK;Almac Charnwood;Oral Granules-PED;tbd;Room Temp.;;;Oral;;;;Meusel,Dr.,Manuela (HP BioP L&I) BIP-DE-I;Solid;Oral Granules;(Blank);(Blank);;;;An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B).;Pediatric line extension of Nerandomilast for pulmonary fibrosis. Uses different manufacturing process (Fluid Bed, outsourced to Almac).;;;
MATCH_LE;Nerandomilast;BI 1015550_SSC;Nerandomilast;Small Molecule;Solid;;Immunology;Phase II;On Track;Systemic Sclerosis;2030;;;Buy;CDMO;Almac, UK;Almac Charnwood;Oral Granules-PED;tbd;Room Temp.;;;Oral;;;;Meusel,Dr.,Manuela (HP BioP L&I) BIP-DE-I;Solid;Oral Granules;(Blank);(Blank);;;;An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B).;Line extension of Nerandomilast for Systemic Sclerosis. Phase II development.;;;
NO_MATCH_export;Nintedanib;;;Small Molecule;Solid;;;;;;;;;Buy;INTERNAL;Biberach;Catalent Eberbach;SG_Capsule;Encapsulation;(Blank);;;;;;;Ruppert,Tanja (HP BioP L&I) BIP-DE-I;Solid;Solids non-standard;Very Low;<1 mio PCS;;;;;;;;
MATCH;Obrixtamig;BI 764532;Obrixtamig;T-cell Engager;Liquid;NME;Oncology;Phase II;On Track;Extra-pulmonale neuroendokrine Karzinome (2L epNEC);2027;;"US; Germany; Japan; China";Buy;;(Blank);Vetter Ravensburg;Sf_Injection;"Sterile Filling; Lyophilization";2 to 8°C;;;Intravenös und subkutan;;;;Schneider,Dr.,Siegfried (HP BioP L&I) BIP-DE-B;NBE;Vial (Standard);Low;>100 mio PCS;;;;Bispezifischer DLL3/CD3 T-Zell-Engager, der DLL3 auf Tumorzellen und CD3 auf T-Zellen bindet zur gezielten Immunaktivierung.;Bispezifischer Antikörper für neuroendokrine Karzinome. Lead indication: 2L epNEC als Monotherapie.;Patienten mit DLL3-positiven neuroendokrinen Karzinomen;;
MATCH_LE;Obrixtamig;BI 764532_EPNEC;Obrixtamig;T-cell Engager;Liquid;;Oncology;Phase Ib/III;On Track;Extra-pulmonale neuroendokrine Karzinome (First-Line);2029;;;Buy;;(Blank);Vetter Ravensburg;Sf_Injection;"Sterile Filling; Lyophilization";2 to 8°C;;;Intravenös und subkutan;;;;Schneider,Dr.,Siegfried (HP BioP L&I) BIP-DE-B;NBE;Vial (Standard);Low;>100 mio PCS;;;;Bispezifischer DLL3/CD3 T-Zell-Engager, der DLL3 auf Tumorzellen und CD3 auf T-Zellen bindet zur gezielten Immunaktivierung.;Line extension of Obrixtamig for first-line epNEC. Combination therapy with Pt/Etoposid (Dareon™-7).;Patients with extra-pulmonary neuroendocrine carcinomas, first-line treatment;;
MATCH_LE;Obrixtamig;BI 764532_SCLC;Obrixtamig;T-cell Engager;Liquid;;Oncology;Phase III;On Track;Extensive-Stage Small Cell Lung Cancer (First-Line);2029;;;Buy;;(Blank);Vetter Ravensburg;Sf_Injection;"Sterile Filling; Lyophilization";2 to 8°C;;;Intravenös und subkutan;;;;Schneider,Dr.,Siegfried (HP BioP L&I) BIP-DE-B;NBE;Vial (Standard);Low;>100 mio PCS;;;;Bispezifischer DLL3/CD3 T-Zell-Engager, der DLL3 auf Tumorzellen und CD3 auf T-Zellen bindet zur gezielten Immunaktivierung.;Line extension of Obrixtamig for first-line ES-SCLC. Combination therapy with Pt/Etoposid + Immunotherapy (Dareon™-9).;Patients with extensive-stage small cell lung cancer, first-line treatment;;
MATCH;Spesolimab;BI 655130;Spesolimab;Monoclonal Antibody;Liquid;NBE;"Immunology; Neutrophilic Dermatoses";Marketed (GPP flares);;Pyoderma Gangrenosum (PG);2027;0;;Make;;(Blank);BI Biberach;Sf_Injection;Sterile Filling;2 to 8°C;;;Injectable;;;;Schneider,Dr.,Siegfried (HP BioP L&I) BIP-DE-B;NBE;Device for s.c. injection;Low;1-10 mio PCS;MED: 2;;;Humanized IgG1 monoclonal antibody antagonizing IL-36 receptor (IL-36R), blocking IL-36α, IL-36β, and IL-36γ signaling.;"Anti-IL-36R monoclonal antibody approved for GPP flares, investigational for pyoderma gangrenosum; IV for flares, SC for prevention.";Adults with active PG lesions.;Systemic Sclerosis (SSc): 1 designation;
MATCH;Survodutide;BI 456906;Survodutide;Peptides;Liquid;NME;Cardiovascular-Renal-Metabolic (CRM);Phase III;Delayed;Obesity;2027;86;;Buy;INTERNAL;BI Biberach;Thermo Fisher Greenville;Sf_Injection-AI;Sterile Filling;2 to 8°C;;;Subkutan;PPG (halted);"Thermo Fisher; ING";Nemera (PEN/Primary);Hennig,Dr.,Rabea (HP BioP L&I) BIP-DE-I;NCE_liquid;Device for s.c. injection;High;>100 mio PCS;HIGH: 2;CRIT: 2;;A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist.;A GCGR/GLP-1 receptor dual agonist for people living with overweight or obesity, and for those with MASH.;People living with overweight or obesity (BMI ≥ 27 kg/m²) and people living with MASH.;Obesity: 2 designations;
MATCH_LE;Survodutide;BI 456906_MASH1;Survodutide;Peptides;Liquid;;Cardiovascular-Renal-Metabolic (CRM);Phase III;Delayed;MASH F2/F3;2028;;;Buy;INTERNAL;BI Biberach;Thermo Fisher Greenville;Sf_Injection-AI;Sterile Filling;2 to 8°C;;;Subkutan;;;;Hennig,Dr.,Rabea (HP BioP L&I) BIP-DE-I;NCE_liquid;Device for s.c. injection;High;>100 mio PCS;;;;A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist.;Line extension of Survodutide for MASH F2/F3. Shares same NME development path, approximately one year behind obesity indication.;People living with MASH F2/F3;;
MATCH_LE;Survodutide;BI 456906_MASH2;Survodutide;Peptides;Liquid;;Cardiovascular-Renal-Metabolic (CRM);;;MASH cF4;2030;;;Buy;INTERNAL;BI Biberach;Thermo Fisher Greenville;Sf_Injection-AI;Sterile Filling;2 to 8°C;;;Subkutan;;;;Hennig,Dr.,Rabea (HP BioP L&I) BIP-DE-I;NCE_liquid;Device for s.c. injection;High;>100 mio PCS;;;;A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist.;Line extension of Survodutide for compensated cirrhosis due to MASH (cF4 stage).;People living with MASH cF4;;
MATCH;Survodutide;BI 456906;Survodutide;Peptides;Liquid;NME;Cardiovascular-Renal-Metabolic (CRM);Phase III;Delayed;Obesity;2027;86;;Make;INTERNAL;BI Biberach;BI Biberach;Sf_Injection-PEN;Sterile Filling;2 to 8°C;;;Subkutan;PPG (halted);"Thermo Fisher; ING";Nemera (PEN/Primary);Duchardt,Dr.,Falk (HP BioP L&I) BIP-DE-I;NCE_liquid;Device for s.c. injection;(Blank);(Blank);HIGH: 2;CRIT: 2;;A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist.;A GCGR/GLP-1 receptor dual agonist for people living with overweight or obesity, and for those with MASH.;People living with overweight or obesity (BMI ≥ 27 kg/m²) and people living with MASH.;Obesity: 2 designations;
MATCH_LE;Survodutide;BI 456906_MASH1;Survodutide;Peptides;Liquid;;Cardiovascular-Renal-Metabolic (CRM);Phase III;Delayed;MASH F2/F3;2028;;;Make;INTERNAL;BI Biberach;BI Biberach;Sf_Injection-PEN;Sterile Filling;2 to 8°C;;;Subkutan;;;;Duchardt,Dr.,Falk (HP BioP L&I) BIP-DE-I;NCE_liquid;Device for s.c. injection;(Blank);(Blank);;;;A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist.;Line extension of Survodutide for MASH F2/F3. Shares same NME development path, approximately one year behind obesity indication.;People living with MASH F2/F3;;
MATCH_LE;Survodutide;BI 456906_MASH2;Survodutide;Peptides;Liquid;;Cardiovascular-Renal-Metabolic (CRM);;;MASH cF4;2030;;;Make;INTERNAL;BI Biberach;BI Biberach;Sf_Injection-PEN;Sterile Filling;2 to 8°C;;;Subkutan;;;;Duchardt,Dr.,Falk (HP BioP L&I) BIP-DE-I;NCE_liquid;Device for s.c. injection;(Blank);(Blank);;;;A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist.;Line extension of Survodutide for compensated cirrhosis due to MASH (cF4 stage).;People living with MASH cF4;;
NO_MATCH_export;T3P-Y058-739;;;LBT;Liquid;;;;;;;;;tbd;;(Blank);tbd;Sf_Injection;Sterile Filling;(Blank);;;;;;;Cullmann,Dr.,Gerhard (HP BioP BioX) BIG-AT-V;NBE;Technology unknown;(Blank);(Blank);;;;;;;;
NO_MATCH_export;Tenecteplase (2nd Gen.);;;Recombinant Proteins;Liquid;;;;;;;;;Make;INTERNAL;(Blank);BI Biberach;Sf_Injection;Sterile Filling;(Blank);;;;;;;Mueller,Dr.,Markus_Michael (HP BioP L&I) BIP-DE-B;NBE;Vial (Standard);Low;1-10 mio PCS;;;;;;;;
MATCH;Tenecteplase;BI XXXXX;Tenecteplase;Recombinant Proteins;Liquid;NME;Neurology / Stroke;Phase III;On Track;Acute Ischemic Stroke (AIS) in extended time window (4.5-24h);2029;;;Make;;(Blank);BI Biberach;Sf_Injection;Sterile Filling;(Blank);;;Intravenous (single bolus);;;;Wiedenmann,Dr.,Alexander (HP BioP L&I) BIP-DE-B;NBE;Vial (Standard);(Blank);(Blank);;;;Tissue Plasminogen Activator - recombinant fibrin-specific thrombolytic agent that converts plasminogen to plasmin.;Tissue plasminogen activator for acute ischemic stroke in extended time window (4.5-24h). Single-bolus administration offers practical advantage over alteplase.;Patients with acute ischemic stroke, including basilar artery occlusion (BAO) up to 24 hours;AIS: 1 designation;
MATCH;Verducatib;BI 1291583;Verducatib;Small Molecule;Solid;NME;"Respiratory; Immunology";Phase III;Delayed;Non-Cystic Fibrosis Bronchiectasis (NCFBE);2029;135;;Make;INTERNAL;BI Biberach;BI Ingelheim;FC_Tablet;Direct Compression;Room Temp.;Low (10 - 1,000 kg);Medium (10 - 100 million PCS);Oral;ING (ongoing);ING_SoL (ongoing);;Schmidt,Dr.,Friedrich (HP BioP L&I) BIP-DE-I;Solid;Solids non-standard;Medium;10-100 mio PCS;HIGH: 3;;;Cathepsin C (CatC) inhibitor.;A CatC inhibitor for inflammatory lung conditions, targeting neutrophil serine proteases activation.;;NCFBE: 1 designation;
MATCH;"Vicadrostat; Empagliflozin";BI 690517;Vicadrostat;Small Molecule;Solid;NME;Cardiovascular-Renal-Metabolic (CRM);Phase III;On Track;Chronic Kidney Disease (CKD);2028;0;;Make;INTERNAL;"BI Japan; BI Biberach";BI Ingelheim;FC_Tablet;Fluid Bed Granulation;Room Temp.;High (> 10 tn);High (> 100 million PCS);Oral;ING @Ingelheim (ongoing);ING_SoL @Ingelheim (ongoing);;Hartig-Heimel,Dr.,Mareke (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;High;>100 mio PCS;;;;A novel, selective, and potent aldosterone synthase inhibitor (ASi).;An aldosterone synthase inhibitor used in combination with empagliflozin for cardiovascular and renal disease.;;;
NO_MATCH_export;"Vicadrostat; Empagliflozin";;;Small Molecule;Solid;;;;;;;;;Make;INTERNAL;"BI Japan; BI Biberach";BI Ingelheim;FC_Tablet;Fluid Bed Granulation;Room Temp.;;;;;;;Hartig-Heimel,Dr.,Mareke (HP BioP L&I) BIP-DE-I;Solid;Film-coated tablet;High;>100 mio PCS;;;;;;;;
MATCH;Vicadrostat;BI 690517;Vicadrostat;Small Molecule;Solid;NME;Cardiovascular-Renal-Metabolic (CRM);Phase III;On Track;Chronic Kidney Disease (CKD);2028;0;;tbd;tbd;(Blank);tbd;Oral Granules-PED;tbd;Room Temp.;High (> 10 tn);High (> 100 million PCS);Oral;ING @Ingelheim (ongoing);ING_SoL @Ingelheim (ongoing);;Hartig-Heimel,Dr.,Mareke (HP BioP L&I) BIP-DE-I;Solid;Oral Granules;(Blank);(Blank);;;;A novel, selective, and potent aldosterone synthase inhibitor (ASi).;An aldosterone synthase inhibitor used in combination with empagliflozin for cardiovascular and renal disease.;;;
MATCH;Zongertinib;BI 1810631;Zongertinib;Small Molecule;Solid;NME;Oncology;Approved/Launched (US, Accelerated Approval 08-Aug-2025);On Track;Non-Small Cell Lung Cancer (NSCLC) with HER2 alterations.;2026;0;US;Hybrid;EACD;Seran;"Hovione Loures; BI Ingelheim";FC_Tablet-SDD;"Organic Spray Drying; Roller Compaction";2 to 8°C;Low (10 - 1,000 kg);Low (1 - 10 million PCS);Oral;"Cambrex (qualified); Alphora (ongoing)";"Hovione (qualified); ING (qualified)";;May,Dr.,Sabine (HP BioP L&I) BIP-DE-I;Solid;Solids non-standard;Low;1-10 mio PCS;HIGH: 1;MED: 1;;Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI).;An irreversible, HER2-selective TKI designed to block uncontrolled cell production in HER2-driven cancers like NSCLC.;Patients with HER2-driven cancers / advanced solid tumors with HER2 gene alterations.;NSCLC: 2 designations;Submitted
MATCH_LE;Zongertinib;BI 1810631_BC1;Zongertinib;Small Molecule;Solid;;Oncology;;;Breast Cancer (Third-Line and Beyond);2029;;;Hybrid;EACD;Seran;"Hovione Loures; BI Ingelheim";FC_Tablet-SDD;"Organic Spray Drying; Roller Compaction";2 to 8°C;;;Oral;;;;May,Dr.,Sabine (HP BioP L&I) BIP-DE-I;Solid;Solids non-standard;Low;1-10 mio PCS;;;;Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI).;Line extension of Zongertinib for third-line and beyond breast cancer with HER2 alterations.;Patients with HER2-driven breast cancer;;
MATCH_LE;Zongertinib;BI 1810631_GC;Zongertinib;Small Molecule;Solid;;Oncology;;;Gastric Cancer (Second-Line);2031;;;Hybrid;EACD;Seran;"Hovione Loures; BI Ingelheim";FC_Tablet-SDD;"Organic Spray Drying; Roller Compaction";2 to 8°C;;;Oral;;;;May,Dr.,Sabine (HP BioP L&I) BIP-DE-I;Solid;Solids non-standard;Low;1-10 mio PCS;;;;Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI).;Line extension of Zongertinib for second-line gastric cancer with HER2 alterations.;Patients with HER2-driven gastric cancer;;
MATCH_LE;Zongertinib;BI 1810631_NSCLC2;Zongertinib;Small Molecule;Solid;;Oncology;Phase III;;Non-Small Cell Lung Cancer (Adjuvant);2031;;;Hybrid;EACD;Seran;"Hovione Loures; BI Ingelheim";FC_Tablet-SDD;"Organic Spray Drying; Roller Compaction";2 to 8°C;;;Oral;;;;May,Dr.,Sabine (HP BioP L&I) BIP-DE-I;Solid;Solids non-standard;Low;1-10 mio PCS;;;;Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI).;Line extension of Zongertinib for adjuvant treatment of NSCLC with HER2 alterations.;Patients with HER2-driven NSCLC in adjuvant setting;;
MATCH_LE;Zongertinib;BI 1810631_BC2;Zongertinib;Small Molecule;Solid;;Oncology;;;Breast Cancer (Second-Line);2032;;;Hybrid;EACD;Seran;"Hovione Loures; BI Ingelheim";FC_Tablet-SDD;"Organic Spray Drying; Roller Compaction";2 to 8°C;;;Oral;;;;May,Dr.,Sabine (HP BioP L&I) BIP-DE-I;Solid;Solids non-standard;Low;1-10 mio PCS;;;;Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI).;Line extension of Zongertinib for second-line breast cancer with HER2 alterations.;Patients with HER2-driven breast cancer;;
NO_MATCH_ps;;BI 1291583_PED;Verducatib PED;Small Molecule;;;"Respiratory; Immunology";Pre-Clinical;;Non-Cystic Fibrosis Bronchiectasis Pediatric;2031;;;;;;;;;;;;Oral;;;;;;;;;;;;Cathepsin C (CatC) inhibitor.;Pediatric line extension of Verducatib for Non-Cystic Fibrosis Bronchiectasis in pediatric populations.;Pediatric patients with Non-Cystic Fibrosis Bronchiectasis;;
NO_MATCH_ps;;BI 1358894;;Small Molecule;;NME;Mental Health;Phase II;Discontinued;Post-Traumatic Stress Disorder (PTSD);;0;;;;;;;;;High (> 10 tn);High (> 100 million PCS);Oral;"ING (qualified); BDC @Biberach (qualified)";ING_SoL @Ingelheim (qualified);;;;;;;;;;TRPC4/5 inhibitor.;A TRPC4/5 inhibitor targeting ion channels implicated in mood and stress-related disorders like PTSD.;;;
NO_MATCH_ps;;BI 1569912;;Small Molecule;;NME;Mental Health;Phase II;Discontinued;Major Depressive Disorder (MDD) - adjunctive therapy;;0;;;;;;;;;;;Oral;;;;;;;;;MED: 1;;;An oral, NMDA subunit 2b-selective negative allosteric modulator (NR2B NAM).;An oral NR2B NAM designed to rapidly relieve depressive symptoms in MDD without dissociative side effects.;;;
NO_MATCH_ps;;BI 1821736;;Gene Therapy;;NBE;Oncology;Discontinued;Discontinued;"HNSCC; Melanoma";;0;;;;;;;;;High (> 30 12k runs);Very Low (< 1 million PCS);Intratumoral (i.t.) und Intravenös (i.v.);Lonza (ongoing);Lonza (ongoing);;;;;;;;;;VSV-GP-CD80-Fc OV (Oncolytic Virus). This is a second-generation oncolytic virus, likely with enhanced immune-stimulatory properties via the CD80-Fc component.;A second-gen oncolytic virus with enhanced immune-stimulation via a CD80-Fc component for HNSCC and Melanoma, administered intratumorally and intravenously.;;;
NO_MATCH_ps;;BI 1839100;;Small Molecule;;NME;Respiratory;Phase II;On Track;IPF/PPF cough;;0;;;;;;;;;;Medium (10 - 100 million PCS);Oral;ING @Ingelheim (ongoing);ING_SoL @Ingelheim (ongoing);;;;;;;;;;TRPA1 inhibitor.;TRPA1-Inhibitor zur Hustenreduktion bei IPF/PPF (zusätzlich krankheitsbezogene Endpunkte in Evaluierung).;;;
NO_MATCH_ps;;BI 3006337;"Not disclosed; Partner-Alias: YH25724";Recombinant Proteins;;NBE (Biologic);Cardiovascular-Renal-Metabolic (CRM);Discontinued;Discontinued;MASH;;0;;;;;;;;;Very Low (< 5 12k runs);Very Low (< 1 million PCS);Subkutan;C(D)MO (ongoing);C(D)MO (ongoing);;;;;;;;;;GLP-1/FGF21 agonist.;Langwirksames hyFc-basiertes duales GLP-1/FGF21-Fc-Fusionsprotein für MASH.;;;
NO_MATCH_ps;;BI 3018078 / BI 3024308;;Gene Therapy;;NBE (Biologic);Oncology;Phase Ib;On Track;Colorectal Cancer (CRC);;0;;;;;;;;;;;Parenteral (kombinationsabhängig);;;;;;;;;;;;"Heterologes Prime-Boost (ATP128 → VSV-GP128) zur Induktion tumor-spezifischer T-Zell-Immunität; in Kombination mit PD-1-Blockade (Ezabenlimab).";"Therapeutischer Protein-Impfstoff (ATP128) + VSV-GP128 als Boost; Evaluierung bei MSS Stadium IV CRC in Kombi mit Ezabenlimab.";;;
NO_MATCH_ps;;BI 3706674;;Small Molecule;;NME;Oncology;Phase I;On Track;"Gastric Cancer (GC); Esophageal Cancer (EC); Gastroesophageal Junction Cancer (GEJC); Pancreatic Ductal Adenocarcinoma (PDAC)";;0;;;;;;;;;;;Oral;EACD (ongoing);EACD (ongoing);;;;;;;HIGH: 1;;;Nicht-kovalenter Multi-KRAS-Inhibitor, der GDP-gebundenes KRAS (wt-amp & mehrere Mutanten, inkl. G12V) bindet.;Monotherapie-Entwicklung bei KRAS-WT-Amplifikationen (GC/EC/GEJ) und KRAS-G12V (u.a. PDAC).;;;
NO_MATCH_ps;;BI 3731579;;Small Molecule;;NME;Inflammation & Respiratory / Respiratory (IPF/PPF);Pre-Clinical;Discontinued;IPF/PPF prevention (IPF/PPFp);2033;0;;;;;;;;;;;oral;;;;;;;;;;;;NOX4 inhibitor.;Oraler NOX4-Inhibitor zur Progressionsverlangsamung bei IPF/PPF (präklinisch).;;;
NO_MATCH_ps;;BI 3793898;;Small Molecule;;NME;Mental Health;Pre-Clinical (post-SoD);On Track;Cognitive Impairment Associated with Schizophrenia (CIAS);;0;;;;;;;;;;;;;;;;;;;;;;;mGluR3 PAM (Positive Allosteric Modulator).;An mGluR3 Positive Allosteric Modulator for Cognitive Impairment Associated with Schizophrenia (CIAS).;;;
NO_MATCH_ps;;BI 3797479;;Small Molecule;;NME;Neuroscience (CIAS – Cognitive Impairment Associated with Schizophrenia);Preclinical / Early Development;;Cognitive Impairment Associated with Schizophrenia (CIAS);2032;0;;;;;;;;;;;Oral;;;;;;;;;HIGH: 1;;;Catechol-O-methyltransferase (COMT) inhibitor that modulates dopamine metabolism to improve cognitive processes.;COMT inhibitor targeting dopamine metabolism for CIAS in schizophrenia.;"Adults with schizophrenia (CIAS); Parkinson’s disease (CIPD)";;
NO_MATCH_ps;;BI 3810539;;Monoclonal Antibody;;NBE;Oncology;Discontinued;Discontinued;"Triple-Negative Breast Cancer (TNBC); Small Cell Lung Cancer (SCLC)";;0;;;;;;;;;;;;;;;;;;;;;;;DLL3 ADC (Antibody-Drug Conjugate).;A DLL3-targeting Antibody-Drug Conjugate (ADC) for Triple-Negative Breast Cancer (TNBC) and Small Cell Lung Cancer (SCLC).;;;
NO_MATCH_ps;;BI 3821001;DcR3-Fc;Recombinant Proteins;;NBE;"Immunology; IBD";Preclinical/SoD (Ende 2024);;Ulcerative Colitis;2035;0;;;;;;;;;;;Injectable;;;;;;;;;MED: 1;;;Engineered decoy receptor 3 fused to silenced IgG1 Fc to neutralize TL1A and LIGHT, reducing inflammation and tissue remodeling in IBD.;Fc‑fusion decoy receptor neutralizing TL1A and LIGHT for inflammation control in ulcerative colitis.;Moderate–severe ulcerative colitis.;;
NO_MATCH_ps;;BI 3822971;Not disclosed;T-cell Engager;;NBE (ntm);Oncology;Preclinical;;NSCLC;2034;0;;;;;;;;;;;"IV; SC (possible later)";;;;;;;;;HIGH: 3;;;"Bispecific antibody binding LY6K-HLA-A*02:01 on tumor cells and CD3ε on T cells to induce tumor-specific cytotoxicity; Fc engineered for half-life extension and reduced effector function.";Bispecific TcE for NSCLC inducing tumor-specific T‑cell cytotoxicity via LY6K‑HLA/CD3 engagement.;;;
NO_MATCH_ps;;BI 3906517;;Peptides;;NME;Cardiovascular-Renal-Metabolic (CRM);Preclinical;On Track;Obesity;;0;;;;;;;;;;;SC (subkutan);;;;;;;;;;;;Triple-Agonist an GCGR/GIPR/GLP-1R.;Long-acting Triple-Agonist für Adipositas.;;;
NO_MATCH_ps;;BI 3972080;CT‑155;Prescription Digital Therapeutic (SaMD/PDT);;DTx;Mental Health / CNS (CREA);"Phase III – pivotal CONVOKE abgeschlossen; primärer Endpunkt erreicht";;Experiential Negative Symptoms in Schizophrenia (XNS SCZ);2026;0;US;;;;;;;;;;Digital (smartphone‑delivered);;;;;;;;;HIGH: 2;MED: 1;;Smartphone‑based PDT delivering evidence‑based psychosocial interventions (adaptive goal setting, cognitive restructuring, behavioral activation, social skills, positive‑affect training). Targets defeatist beliefs and promotes real‑world engagement to reduce experiential negative symptoms as an adjunct to standard‑of‑care antipsychotics.;Digital therapeutic for negative symptoms in schizophrenia;Adults with schizophrenia on stable antipsychotic therapy, experiencing moderate–severe experiential negative symptoms;XNS_SCZ: 1 designation;Targeted first submission: Jan 23, 2026
NO_MATCH_ps;;BI 4018711;CT‑156 (working title);Prescription Digital Therapeutic (SaMD/PDT);;DTx (SaMD);Schizophrenia / Neuroscience (TA CREA);Phase II;;Functional Impairment in Schizophrenia (FI SCZ);2028;0;US;;;;;;;;;;Digital (software‑delivered intervention);;;;;;;;;HIGH: 3;;;Software‑based prescription digital therapeutic designed to improve functional outcomes in schizophrenia through structured behavioral interventions delivered via a mobile platform.;Digital therapeutic to improve functional outcomes in schizophrenia via mobile behavioral interventions;Patients with schizophrenia experiencing functional impairment;;No active submission
NO_MATCH_ps;;BI 4041979;T3P-Y058-739 (Not disclosed);Gene Therapy;;NME;Oncology / Immuno-Oncology;Phase I;On Track;Head and Neck Squamous Cell Carcinoma (HNSCC), Melanoma;2032;;;;;;;;;;;;Intratumoral (IT) and Intravenous (IV);;;;;;;;;HIGH: 4 | MED: 2;;;Dual innate immunity activator (cGAS/RIG-I) via genetically modified Yersinia enterocolitica - bacterial vector immunotherapy that selectively colonizes tumors and delivers immune modulators via Type III secretion system. Activates both cGAS → cGAMP → STING pathway and RIG-I → MAVS/IRF3 signaling, inducing strong Type I Interferon signature to 'heat up' tumor microenvironment.;Bacterial vector immunotherapy (attenuated Y. enterocolitica) activating innate immunity via dual cGAS/RIG-I pathways. Phase I evaluating intratumoral and intravenous routes as monotherapy and in combination with PD-1 inhibitors in HNSCC and melanoma.;Patients with advanced solid tumors (HNSCC, melanoma) in monotherapy or combination with PD-1 inhibitors;Development: 2 designations;
NO_MATCH_ps;;BI 456906_GEN2;Survodutide 2nd Gen;Peptides;;;Cardiovascular-Renal-Metabolic (CRM);;;Obesity;2029;;;;;;;;;;;;Subkutan;;;;;;;;;;;;A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist.;Second generation drug substance formulation of Survodutide. New 'formulation 2.0' development.;People living with overweight or obesity (BMI ≥ 27 kg/m²);;
NO_MATCH_ps;;BI 456906_PED;Survodutide PED;Peptides;;;Cardiovascular-Renal-Metabolic (CRM);Pre-Clinical;;"Pediatric Obesity; MASH";2031;;;;;;;;;;;;Subkutan;;;;;;;;;;;;A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist.;Pediatric line extension of Survodutide for obesity and MASH in pediatric populations.;Pediatric patients with overweight/obesity or MASH;;
NO_MATCH_ps;;BI 456906_PEN;Survodutide PEN;Peptides;;;Cardiovascular-Renal-Metabolic (CRM);Development;On Track;Obesity;2028;;;;;;;;;;;;Subkutan;;;;;;;;;;;;A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist.;PEN device line extension of Survodutide for obesity. Nemera volume ramp-up scenario is key focus.;People living with overweight or obesity (BMI ≥ 27 kg/m²);;
NO_MATCH_ps;;BI 685509;Avenciguat;Small Molecule;;NME;Immunology (Systemische Sklerose) und CRM/Nephrologie (Glomerulonephritiden);Phase II (SSc) and Phase III (GN);On Track;Glomerulonephritis (GN);2028;0;;;;;;;;;Medium (1 - 10 tn);High (> 100 mio PCS);Oral;ING @Ingelheim (ongoing);ING_SoL @Ingelheim (ongoing);;;;;;;;;;A soluble guanylate cyclase (sGC) activator.;An sGC activator for fibrotic and vascular diseases, with active development in Systemic Sclerosis (Phase II) and Glomerulonephritis (Phase III).;;SSc: 1 designation;
NO_MATCH_ps;;BI 685509_PED;Avenciguat PED;Small Molecule;;;Immunology;Pre-Clinical;;Systemic Sclerosis Pediatric;2034;;;;;;;;;;;;Oral;;;;;;;;;;;;A soluble guanylate cyclase (sGC) activator.;Pediatric line extension of Avenciguat for Systemic Sclerosis in pediatric populations.;Pediatric patients with Systemic Sclerosis;;
NO_MATCH_ps;;BI 685509_SSC;Avenciguat;Small Molecule;;;Immunology;Phase II;On Track;Systemic Sclerosis;2030;;;;;;;;;;;;Oral;;;;;;;;;;;;A soluble guanylate cyclase (sGC) activator.;Line extension of Avenciguat for Systemic Sclerosis. sGC activator for fibrotic and vascular disease. Fast Track Designation granted.;Patients with Systemic Sclerosis;SSc: 1 designation;
NO_MATCH_ps;;BI 690517_CVRR;Vicadrostat + empagliflozin;Small Molecule;;;Cardiovascular-Renal-Metabolic (CRM);;;CVRR;2031;;;;;;;;;;;;Oral;;;;;;;;;;;;A novel, selective, and potent aldosterone synthase inhibitor (ASi) in combination with SGLT2 inhibitor.;Line extension of Vicadrostat in combination with empagliflozin for cardiovascular-renal risk reduction.;Patients at high cardiovascular-renal risk;;
NO_MATCH_ps;;BI 690517_HFPEF;Vicadrostat + empagliflozin;Small Molecule;;;Cardiovascular-Renal-Metabolic (CRM);Phase III;On Track;HFpEF;2029;;;;;;;;;;;;Oral;;;;;;;;;;;;A novel, selective, and potent aldosterone synthase inhibitor (ASi) in combination with SGLT2 inhibitor.;Line extension of Vicadrostat in combination with empagliflozin for heart failure with preserved ejection fraction. Developed in parallel with CKD indication.;Patients with HFpEF on top of standard of care;;
NO_MATCH_ps;;BI 690517_HFREF;Vicadrostat + empagliflozin;Small Molecule;;;Cardiovascular-Renal-Metabolic (CRM);;;HFrEF;2030;;;;;;;;;;;;Oral;;;;;;;;;;;;A novel, selective, and potent aldosterone synthase inhibitor (ASi) in combination with SGLT2 inhibitor.;Line extension of Vicadrostat in combination with empagliflozin for heart failure with reduced ejection fraction.;Patients with HFrEF on top of standard of care;;
NO_MATCH_ps;;BI 690517_PED;Vicadrostat + empagliflozin PED;Small Molecule;;;Cardiovascular-Renal-Metabolic (CRM);Pre-Clinical;;CKD Pediatric;2035;;;;;;;;;;;;Oral;;;;;;;;;;;;A novel, selective, and potent aldosterone synthase inhibitor (ASi) in combination with SGLT2 inhibitor.;Pediatric line extension of Vicadrostat in combination with empagliflozin for chronic kidney disease in pediatric populations.;Pediatric patients with CKD;;
NO_MATCH_ps;;BI 706321;;Small Molecule;;NME;Immunology;Discontinued;Discontinued;Crohn's Disease (CD);;0;;;;;;;;;;;Oral;;;;;;;;;;;;RIPK2 inhibitor.;A RIPK2 inhibitor targeting the NOD signaling pathway involved in innate immunity and inflammation in IBD.;;;
NO_MATCH_ps;;BI 754132;Not disclosed;Small Molecule;;NME;Eye Health;Discontinued;Discontinued;Geographic Atrophy (GA);;0;;;;;;;;;;;Intravitreal;;;;;;;;;;;;TrkB activator.;A TrkB activator designed to have neuroprotective effects in the retina for conditions like Geographic Atrophy (GA), administered via intravitreal injection.;;;
NO_MATCH_ps;;BI 765128;;Monoclonal Antibody;;NBE;Eye Health;Phase I/II (PARTRIDGE 1451-0001);Discontinued;Diabetic Retinopathy (DR);2030;0;;;;;;;;;Very Low (<5 12k runs);Very Low (<1 million PCS);Intravitreal;Rentschler @N/A (qualified);Vetter @N/A (qualified);;;;;;;;;;Anti-NRP1 antibody.;Anti-NRP1 mAb for diabetic macular ischemia (DMI).;Patients with diabetic retinopathy;;
NO_MATCH_ps;;BI 765243;;Recombinant Proteins;;NBE;Eye Health;Pre-Clinical;Discontinued;Wet AMD (nAMD);;0;;;;;;;;;;;;;;;;;;;;;;;TrkB/anti-VEGF (bispecific).;Bispecific protein targeting TrkB and VEGF for wet AMD;;;
NO_MATCH_ps;;BI 765250;;Monoclonal Antibody;;NBE;Immunology;"Phase I (SRD abgeschlossen; MRD laufend/PoCP-Vorbereitung)";On Track;Systemic Sclerosis (SSc);;0;;;;;;;;;;;"Intravenös; Subkutan";;;;;;;;;;;;PD-1 agonist.;A PD-1 agonist antibody for immunological conditions like Systemic Sclerosis (SSc).;;;
NO_MATCH_ps;;BI 765845;Not disclosed (internal: G5 MYDGF);Recombinant Proteins;;NME;Cardiovascular-Renal-Metabolic (CRM);Phase II;On Track;ST-Elevation Myocardial Infarction (STEMI);2031;;;;;;;;;;;;Intravenous (Single-Dose in catheterization lab);;;;;;;;;HIGH: 1;;;Myeloid-Derived Growth Factor (MYDGF) - recombinant protein designed for tissue protection and cardiac repair post-STEMI. Reduces cardiomyocyte apoptosis from reperfusion injury and promotes angiogenesis for improved cardiac regeneration.;Recombinant MYDGF protein for acute STEMI treatment. Single IV bolus in catheterization lab during primary PCI to reduce reperfusion injury.;STEMI patients with complete or near-complete coronary occlusion undergoing primary PCI;;
